Related Experiment Video
Updated: Mar 14, 2026
08:11
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
3.7K
Hyperkalemia in Heart Failure.
Chaudhry M S Sarwar1, Lampros Papadimitriou1, Bertram Pitt2
1Cardiology Division, Stony Brook University, Stony Brook, New York.
Journal of the American College of Cardiology
|October 1, 2016
Summary
Heart failure patients with hyperkalemia face increased arrhythmia risks. Novel potassium binders offer new management options, potentially enabling better heart failure treatment with renin-angiotensin-aldosterone system inhibitors.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Potassium homeostasis disorders exacerbate arrhythmia risk in heart failure patients.
- High prevalence of chronic kidney disease in heart failure increases hyperkalemia risk, particularly with renin-angiotensin-aldosterone system inhibitors.
- Acute hyperkalemia treatments may lack long-term tolerability.
Purpose of the Study:
- To review the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure.
- To provide an overview of traditional and novel hyperkalemia management strategies.
- To discuss the need for further research in optimizing heart failure management.
Main Methods:
- Literature review of epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure.
- Analysis of traditional and emerging therapeutic approaches for hyperkalemia.
- Discussion of clinical trial data on novel potassium binders (patiromer, sodium zirconium cyclosilicate).
Main Results:
- Novel potassium binders demonstrate potential for chronic management of hyperkalemia.
- These agents may facilitate the use of renin-angiotensin-aldosterone system inhibitors in previously intolerant patients.
- Optimized hyperkalemia management is crucial for improving heart failure outcomes.
Conclusions:
- New potassium-binding therapies offer promising avenues for managing hyperkalemia in heart failure.
- Improved hyperkalemia control could enhance the efficacy of renin-angiotensin-aldosterone system inhibitors.
- Further research is essential to integrate these findings into optimal heart failure care pathways.
Keywords:
angiotensin-converting enzyme inhibitorsangiotensin-receptor blockerschronic kidney diseasemineralocorticoid receptor antagonistpatiromersodium zirconium cyclosilicateMore Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
11.1K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.1K
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:17Pathophysiology of Heart Failure
4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
01:27Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K